



March 14, 2014

Company Name 3 - D Matrix, Ltd.  
Address 3-2-4, Kojimachi, Chiyoda, Tokyo  
President Kentaro Takamura  
Code Number 7777  
Contact Director Tomoyuki Arai  
TEL +81 3 (3511)3440

### Revision of Forecast of Financial Results for FY2013

The company hereby announces that it revised its forecast of financial results for FY2013 (May 1, 2013 to April 30, 2014) which was previously announced on June 13, 2013.

1. Revision of forecast of financial results for FY2013 (May 1, 2013 to April 30, 2014)

[Consolidated]

(Millions of yen, %)

	Business revenue	Operating income (loss)	Ordinary income (loss)	Net income (loss)	Net income(loss) per share
Forecast announced previously (A)	4,178	1,658	1,646	1,491	Yen 78.76
<b>Revised forecast (B)</b>	<b>106</b>	<b>(1,464)</b>	<b>(1,475)</b>	<b>(1,476)</b>	<b>(75.57)</b>
Change (B-A)	(4,072)	(3,122)	(3,121)	(2,967)	—
Change (%)	(97.4)	—	—	—	—
Reference: Previous year results (FY2012)	32	(999)	(977)	(978)	(52.63)

[Non-consolidated]

(Millions of yen, %)

	Business revenue	Operating income (loss)	Ordinary income (loss)	Net income (loss)	Net income(loss) per share
Forecast announced previously (A)	3,019	1,360	1,348	1,267	Yen 66.93
<b>Revised forecast (B)</b>	<b>56</b>	<b>(1,079)</b>	<b>(1,100)</b>	<b>(1,101)</b>	<b>(56.41)</b>
Change (B-A)	(2,963)	(2,439)	(2,448)	(2,368)	—
Change (%)	(98.1)	—	—	—	—
Reference: Previous year results (FY2012)	32	(795)	(803)	(804)	(43.29)

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ significantly from the forecast due to various subsequent factors.

Note: Net income (loss) per share is calculated with the average number of shares outstanding including 700,000 shares which was issued through public offering on July 24, 2013. Hence, net income (loss) per share for FY2012 has been adjusted to reflect this public offering.

## 2. Reasons of revision (for both consolidated and non-consolidated financial results)

The company's group has been developing medical devices with our self-assembling peptide technology. For the primary pipeline, hemostat (TDM-621), the group successfully obtained a conformity certification for CE marking, which allows us to sell the products in the EU countries and to have a big advance in our business. The group further plans to promote marketing in Asia-Oceania and Latin American regions using with this CE marking. In US, the review of IDE for conducting clinical trial reached the final phase before starting trial.

However, the review for manufacturing and marketing approval in Japan still continues, which affects the company's financial results. Therefore, the company revised its forecast of financial results for FY2013 mainly due to the reasons stated below.

### [Business Revenue]

In this fiscal year, the company anticipated to obtain manufacturing and marketing approval of TDM-621 in Japan and estimated milestone payment income upon the approval and product sales revenue in its forecast of financial results for FY2013. The company also planned to acquire milestone payment income from distribution partner in US through partnership agreement for sales in the country.

However, the review by the Pharmaceuticals and Medical Devices Agency, Japan (PMDA) for manufacturing and marketing approval in Japan still continues even though the company has been discussing with PMDA, and the approval is likely to be postponed to FY2014. Hence, milestone payments and product sales resulting from this business progress will be received in FY2014 rather than FY2013.

The company has also been negotiating with several distributors for sales in EU and US and the agreement is likely to be entered into in FY2014. Concluding a distribution agreement with better conditions between the best partner and us is regarded as one of the top priorities since the market size in EU/US is large which contributes to increase of our business revenue. Therefore, the company estimates that milestone payments from this agreement will be received in FY2014.

As a result, the previously forecasted operating revenue of ¥4,178 million is revised downward to ¥106 million.

### [Expenses and operating income]

Although expected expenses for both R&D and SGA are fairly in line with our original projections, operating income is also revised downward primarily because of the business revenue decrease.

As a result, our revised forecast consolidated operating loss for FY2013 is ¥1,464 million (down ¥3,122 million from previous forecast), with ordinary loss of ¥1,475 million (down ¥3,121 million) and net loss of ¥1,476 million (down ¥2,967 million). Similarly for non-consolidated results, operating loss of ¥1,079 million (down ¥2,439 million), ordinary loss of ¥1,100 million (down ¥2,448 million), and net loss of ¥1,101 million (down ¥2,368 million) are the revised projections.

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ significantly from the forecast due to various subsequent factors.

[For reference]

Revision of mid-term business plan (consolidated)

The company also revised its mid-term business plan as follows mainly due to the milestone payments income and product sales revenue being received in FY2014 rather than FY2013. For details, please refer to our notification “Revision of mid-term business plan” also announced on the same date.

(Millions of yen)

	Business revenue	Operating income (loss)	Ordinary income (loss)	Net income (loss)
FY2013 (forecast)	106	(1,464)	(1,475)	(1,476)
FY2014 (target)	10,306	4,562	4,548	3,548
FY2015 (target)	13,497	6,436	6,422	4,011

Note: Figures above are extracted from the company's revised mid-term business plan announced on March 14, 2014.

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ significantly from the forecast due to various subsequent factors.